Careprost contains bimatoprost as its active component. This article provides an evidence-based, non-promotional overview of bimatoprost, the prostaglandin analog found in the Careprost bottle (3 ml). It is intended for adult patients in Hong Kong and follows current regulatory guidance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Bimatoprost belongs to the prostaglandin-F (PGF) analog class. After topical ocular administration, the molecule penetrates the cornea and binds to prostanoid FP receptors located in the trabecular meshwork and uveoscleral outflow pathways. Activation of these receptors leads to remodeling of extracellular matrix components, which increases aqueous humor outflow and lowers intra-ocular pressure (IOP).
When used on the eyelid margin, the same FP-receptor activation stimulates the anagen (growth) phase of the eyelash hair follicle, resulting in longer, thicker lashes. The drug’s onset of pressure-lowering effect typically occurs within 4 hours, with peak IOP reduction seen after 8-12 hours. Duration of action extends to about 24 hours, allowing once-daily dosing.
Approved medical uses (based on FDA and EMA labeling)
These indications are consistent across most regulatory regions, including Hong Kong where ophthalmic prostaglandin analogs are prescribed under the same clinical criteria as in the United States and Europe.
Off-label use for eyelash growth (hypotrichosis)
Clinical trials of the branded formulation Latisse (bimatoprost 0.03 %) have demonstrated increased eyelash length, thickness, and darkness after 12 weeks of nightly use. Although Careprost is not FDA-approved for this purpose, many ophthalmologists and dermatologists in Hong Kong are aware of the evidence.
Absolute contraindications
Relative contraindications
Special populations
When specific interaction data for Careprost are limited, patients should inform their healthcare provider of all ocular and systemic medications, including over-the-counter products and herbal supplements.
If the exact dosing regimen cannot be confirmed for a particular patient, clinicians should individualize therapy based on IOP response and tolerance.
Patients using Careprost for off-label eyelash enhancement should have periodic ocular examinations to ensure no adverse pressure changes or ocular surface complications arise.
This article provides educational information about Careprost and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, bimatoprost can be administered while wearing contacts, but it is advisable to remove the lenses before instilling the drop and wait at least 15 minutes before reinserting them to avoid drug absorption onto the lens surface.
Bimatoprost may cause a gradual, permanent increase in brown pigmentation of the iris, especially in patients with mixed-color eyes. The change is typically irreversible.
Prostaglandin analogs cross the placenta, and safety data in pregnant women are limited. Unless the therapeutic benefit clearly outweighs potential risks, use is generally avoided during pregnancy.
IOP reduction can be observed within a few hours after the first dose, with maximal effect occurring around 8-12 hours. Consistent nightly dosing maintains pressure control.
Mild conjunctival hyperemia is common and often resolves with continued use. If redness is severe, painful, or accompanied by vision changes, seek ophthalmic evaluation promptly.
Bimatoprost has been studied primarily for eyelash enhancement. Off-label use on eyebrows is not well-documented, and safety cannot be guaranteed. Discuss any such use with an eye-care professional.
Systemic absorption from ocular dosing is minimal. Rare systemic effects may include headache or mild respiratory symptoms, but these are uncommon.
Do not throw the bottle into recycling bins. Follow local hazardous-waste guidelines or return it to a pharmacy that offers medication take-back programs.
Yes, bimatoprost-containing eye drops are prescription-only medications in Hong Kong and must be obtained through a licensed pharmacist with a valid doctor's order.
When traveling, keep the bottle in its original packaging with the prescription label visible. Check destination country regulations for ophthalmic drugs and declare the medication if required.
